PMID- 31616637 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study. PG - 932 LID - 10.3389/fonc.2019.00932 [doi] LID - 932 AB - Background and Purpose: Larynx cancer represents one of the most frequently diagnosed head and neck malignancies, which is most often confined to the glottic area. The aim of this study was to report the oncological outcome and identify prognostic factors in early-stage glottic squamous cell carcinoma treated with radiotherapy. Material and Methods: Patients (n = 761) diagnosed and treated in 10 centers between 1990 and 2015 were retrospectively analyzed. Probabilities of loco-regional control (LRC) and overall survival (OS) were calculated and possible prognostic factors were analyzed using Cox proportional hazards models. Results: The median follow-up was 63 months (range: 2-243). Three hundred and sixty-four, 148 and 249 patients had cT1a, cT1b, and cT2 stage I-II disease, respectively. Five and 10-years LRC/OS rates in the whole cohort were 83/82% and 80/68%, respectively. Three patients developed distant recurrences. In univariate analysis, male sex (HR: 3.49; 95% CI: 1.47-11.37; p < 0.01), T2 vs. T1a (HR: 1.62; 95% CI: 1.08-2.43; p = 0.02) and anterior commissure involvement (ACI) (HR: 1.66; 95% CI: 1.38-2.45; p < 0.01) were associated with impaired LRC. In multivariate analysis, male sex (HR: 3.42; 95% CI: 1.44-11.17; p < 0.01) and ACI (HR: 1.51; 95% CI: 1.01-2.28; p = 0.047) remained poor prognostic factors. No relation of treatment technique and biologically equivalent dose (BED) to oncological outcome was identified except for higher BED(10)(L = 25; T = 1) yielding better LRC in T1a tumors (p = 0.04) in univariate analyses. Conclusion: Our results highlight the negative impact of ACI on tumor control. A less-expected finding was the impact of sex on tumor control. Further research is needed to validate its prognostic value and investigate any related biologic or behavioral factors, which may be modified to improve oncologic outcome. CI - Copyright (c) 2019 Elicin, Ermis, Oehler, Aebersold, Caparrotti, Zimmermann, Studer, Henke, Adam, Anschuetz, Ozsahin, Guckenberger, Shelan, Kaydihan, Riesterer, Prestwich, Spielmann, Giger and Sen. FAU - Elicin, Olgun AU - Elicin O AD - Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Ermis, Ekin AU - Ermis E AD - Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. AD - Department of Clinical Oncology, Leeds Cancer Center, St. James's Institute of Oncology, Leeds, United Kingdom. FAU - Oehler, Christoph AU - Oehler C AD - Department of Radiation Oncology, Cantonal Hospital of Graubunden, Chur, Switzerland. FAU - Aebersold, Daniel M AU - Aebersold DM AD - Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Caparrotti, Francesca AU - Caparrotti F AD - Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland. FAU - Zimmermann, Frank AU - Zimmermann F AD - Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland. FAU - Studer, Gabriela AU - Studer G AD - Department of Radiation Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland. AD - Department of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland. FAU - Henke, Guido AU - Henke G AD - Department of Radiation Oncology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland. FAU - Adam, Lukas AU - Adam L AD - Department of Radiation Oncology, Cantonal Hospital of Graubunden, Chur, Switzerland. FAU - Anschuetz, Lukas AU - Anschuetz L AD - Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Ozsahin, Mahmut AU - Ozsahin M AD - Department of Radiation Oncology, University Hospital of Lausanne, Lausanne, Switzerland. FAU - Guckenberger, Matthias AU - Guckenberger M AD - Department of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland. FAU - Shelan, Mohamed AU - Shelan M AD - Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Kaydihan, Nuri AU - Kaydihan N AD - Department of Radiation Oncology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Riesterer, Oliver AU - Riesterer O AD - Department of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland. FAU - Prestwich, Robin J D AU - Prestwich RJD AD - Department of Clinical Oncology, Leeds Cancer Center, St. James's Institute of Oncology, Leeds, United Kingdom. FAU - Spielmann, Thierry AU - Spielmann T AD - Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland. FAU - Giger, Roland AU - Giger R AD - Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Sen, Mehmet AU - Sen M AD - Department of Clinical Oncology, Leeds Cancer Center, St. James's Institute of Oncology, Leeds, United Kingdom. LA - eng PT - Journal Article DEP - 20190920 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6763757 OTO - NOTNLM OT - head and neck cancer OT - larynx cancer OT - radiotherapy OT - sex OT - squamous cell carcinoma EDAT- 2019/10/17 06:00 MHDA- 2019/10/17 06:01 PMCR- 2019/01/01 CRDT- 2019/10/17 06:00 PHST- 2019/06/05 00:00 [received] PHST- 2019/09/05 00:00 [accepted] PHST- 2019/10/17 06:00 [entrez] PHST- 2019/10/17 06:00 [pubmed] PHST- 2019/10/17 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.00932 [doi] PST - epublish SO - Front Oncol. 2019 Sep 20;9:932. doi: 10.3389/fonc.2019.00932. eCollection 2019.